DBV Technologies (DBVT)

Currency in USD
9.455
-0.320(-3.27%)
Closed·
After Hours
9.500+0.045(+0.48%)
·
DBVT Scorecard
Full Analysis
Quickly burning through cash
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.40510.415
52 wk Range
2.20512.780
Key Statistics
Prev. Close
9.775
Open
10.35
Day's Range
9.405-10.415
52 wk Range
2.205-12.78
Volume
60.97K
Average Volume (3m)
52.31K
1-Year Change
83.59%
Book Value / Share
0.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.080
Upside
+70.07%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

DBV Technologies News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

DBV Technologies Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
106

DBV Technologies SWOT Analysis


Allergy Innovation
DBV Technologies' Viaskin Peanut patch offers a novel approach to treating peanut allergies in children, potentially addressing a significant unmet medical need.
Clinical Promise
Explore the compelling efficacy data from long-term trials, showing increased tolerance in toddlers and positioning Viaskin Peanut as a potential game-changer.
Market Potential
Analysts project peak sales potential exceeding $2 billion annually, with price targets ranging from $7.41 to $21.39, reflecting optimism in the product's future.
Pivotal Milestones
Learn about the critical VITESSE trial and regulatory pathway, which could pave the way for a BLA submission and potential market entry by 2026.
Read full SWOT analysis

DBV Technologies Earnings Call Summary for Q2/2024

  • DBV Technologies advances Viaskin Peanut trials; VITESSE Phase 3 enrollment for ages 4-7 to complete by Q3 end
  • Net loss of $60.5M in H1 2024; cash runway extended to Q1 2025 through cost-saving measures
  • FDA feedback pending on labeling approach for toddlers aged 1-3; EPITOPE trial year 3 results expected later in 2024
  • Operating expenses at $65M, including $24M non-recurring costs; cash used in operations totaled $70M
  • Company optimistic about FDA agreement on labeling; emphasizes patient experience data importance
Last Updated: 31/07/2024, 23:54
Read Full Transcript

Compare DBVT to Peers and Sector

Metrics to compare
DBVT
Peers
Sector
Relationship
P/E Ratio
−2.4x−0.9x−0.5x
PEG Ratio
0.060.000.00
Price/Book
95.0x2.6x2.6x
Price / LTM Sales
78.1x3.4x3.2x
Upside (Analyst Target)
79.3%72.1%41.7%
Fair Value Upside
Unlock10.7%6.1%Unlock

Analyst Ratings

3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 16.080
(+70.07% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-0.26 / --
Revenue / Forecast
753.00K / --
EPS Revisions
Last 90 days

DBVT Income Statement

People Also Watch

11.13
VERV
+0.27%
38.330
ARQQ
-2.44%
9.640
QSG
+4.33%
3.290
PROK
+0.92%
103.95
INSM
+0.42%

FAQ

What Stock Exchange Does DBV Technologies Trade On?

DBV Technologies is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for DBV Technologies?

The stock symbol for DBV Technologies is "DBVT."

What Is the DBV Technologies Market Cap?

As of today, DBV Technologies market cap is 273.28M.

What Is DBV Technologies's Earnings Per Share (TTM)?

The DBV Technologies EPS (TTM) is -1.15.

From a Technical Analysis Perspective, Is DBVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has DBV Technologies Stock Split?

DBV Technologies has split 2 times.

How Many Employees Does DBV Technologies Have?

DBV Technologies has 106 employees.

What is the current trading status of DBV Technologies (DBVT)?

As of 26 Jul 2025, DBV Technologies (DBVT) is trading at a price of 9.46, with a previous close of 9.78. The stock has fluctuated within a day range of 9.41 to 10.42, while its 52-week range spans from 2.21 to 12.78.

What Is DBV Technologies (DBVT) Price Target According to Analysts?

The average 12-month price target for DBV Technologies is USD16.08044627, with a high estimate of USD21.21197886 and a low estimate of USD7.53846154. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +70.07% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.